G1 Therapeutics reports Q1 EPS (53c), consensus (64c)

Reports Q1 revenue $12.9M, consensus $11.19M. As of March 31 cash and cash equivalents and marketable securities totaled $116.3M, compared to $145.1M as of December 31, 2022. "Since the start of 2023, we’ve focused efforts on our three core priorities of driving significant growth in sales of COSELA, executing on our four ongoing clinical trials of trilaciclib, and efficiently managing our cash runway through each of our data readouts," said Jack Bailey, CEO of G1 Therapeutics. "We made good progress on all fronts during the Q1 of this year. The commercial team executed well, driving net COSELA sales growth of 18% quarter-over-quarter, and vial volume growth of 21%, as we work towards our guidance of between $50 M-$60M in product revenue this year. Regarding the clinical pipeline, we’ve continued to move each of our trials forward, including our two Phase 2 trials in TNBC from which data are expected later this quarter, followed by results from our pivotal Phase 3 trial in TNBC which are now expected in the Q1 of next year."